Trial Profile
A Prospective Phase II, Randomized Multi-center Trial of a Combined Modularized Treatment With Metronomic Low-dose Treosulfan, Pioglitazone and Clarithromycin Versus Nivolumab in Patients With Squamous Cell Lung Cancer and Non- Squamous Cell Lung Cancer, Respectively After Platin Failure
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Clarithromycin (Primary) ; Pioglitazone (Primary) ; Treosulfan (Primary) ; Nivolumab
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms ModuLung
- 01 Oct 2019 Status changed from recruiting to discontinued according to results presented at the 44th European Society for Medical Oncology Congress
- 27 Mar 2019 This trial has been completed in Germany, according to European Clinical Trials Database.
- 16 Jan 2018 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2019.